Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Am J Clin Oncol Retrieve available abstracts of 36 articles: HTML format

Single Articles

September 2025
1. SHEMBESH RH, Beshr MS, Elhadi M
   Letter to Editor on Qureshi et al. Efficacy and Safety of Abemaciclib in Combination with Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer a Systematic Review and Meta-Analysis, Am J Clin Oncol, 2025, 48(1).
   Am J Clin Oncol. 2025;48:477-478.
   PubMed    
   
   
   August 2025
2. EL FAKIH A, Loap P, Cabel L, Allali S, et al
   Real-world Safety of Concurrent Pembrolizumab and Radiotherapy in Triple-negative Breast Cancer.
   Am J Clin Oncol. 2025 Aug 8. doi: 10.1097/COC.0000000000001236.
   PubMed     Abstract available
   
   
   
3. JAIN D, Upreti K, Tak TK, Date SS, et al
   Predicting and Optimizing Synergistic Drug Combinations for Breast Cancer Treatment Using Machine Learning.
   Am J Clin Oncol. 2025 Aug 6. doi: 10.1097/COC.0000000000001244.
   PubMed     Abstract available
   
   
   
4. TALEB I, Witmeyer S, Charitansky H, Auriol S, et al
   Adenoid Cystic Carcinoma of the Breast and Adjuvant Radiation Therapy: A Review of Literature.
   Am J Clin Oncol. 2025;48:392-398.
   PubMed     Abstract available
   
   
   July 2025
5. STEPHENS MJ, Kasliwal N, Burnette UJ, Onyewadume L, et al
   Impact of Chemotherapy on Financial Toxicity in African American Breast Cancer Patients: Early Findings From the Navigator-Assisted Hypofractionation Phase I Clinical Trial.
   Am J Clin Oncol. 2025 Jul 31. doi: 10.1097/COC.0000000000001241.
   PubMed     Abstract available
   
   
   
6. ONYEWADUME L, Burnette U, Flores LE, McClelland S 3rd, et al
   Navigator-Assisted Hypofractionation Program Survey Validation for African American Breast Cancer Patients.
   Am J Clin Oncol. 2025 Jul 31. doi: 10.1097/COC.0000000000001242.
   PubMed    
   
   
   
7. BOUZIANE J, Loap P, Allali S, Escalup L, et al
   Concurrent Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: Assessing the Efficacy.
   Am J Clin Oncol. 2025 Jul 16. doi: 10.1097/COC.0000000000001237.
   PubMed     Abstract available
   
   
   
8. KARDOKUS K, Stark KA, Lam AB, McClelland S 3rd, et al
   Breast Cancer Patient Treatment Experience at a National Cancer Institute-Designated Cancer Center Before Formal Navigation Integration.
   Am J Clin Oncol. 2025 Jul 14. doi: 10.1097/COC.0000000000001231.
   PubMed     Abstract available
   
   
   
9. ARABSHOMALI A, Goswami S, Masurkar PP
   Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.
   Am J Clin Oncol. 2025 Jul 11. doi: 10.1097/COC.0000000000001209.
   PubMed     Abstract available
   
   
   
10. GREGSTON J, Etzold N, Stratemeier N, McClelland S 3rd, et al
    Assessing the Rate and Quality of Breast Cancer Treatment Following Initial Diagnosis.
    Am J Clin Oncol. 2025 Jul 4. doi: 10.1097/COC.0000000000001229.
    PubMed     Abstract available
    
    
    
11. CULBERT MM, Oladeru OT, Brooks ED, Burchianti T, et al
    Empowering Self-advocacy for Breast Health: A Successful Educational Campaign on Breast Cancer Risk and Screening Recommendations.
    Am J Clin Oncol. 2025 Jul 3. doi: 10.1097/COC.0000000000001219.
    PubMed     Abstract available
    
    
    
12. IQBAL H, Juneja B, Chryssofos S, Ahlawat S, et al
    Complications of Implant-Based Reconstruction and Postmastectomy Radiation in the Era of Adjuvant CDK4/6 Inhibitors.
    Am J Clin Oncol. 2025;48:357-361.
    PubMed     Abstract available
    
    
    May 2025
13. MARTORANA F, Sano MV, Fabi A, Paris I, et al
    A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Am J Clin Oncol. 2025 May 19. doi: 10.1097/COC.0000000000001201.
    PubMed     Abstract available
    
    
    April 2025
14. LOAP P, Chabli S, Cottu P, Kirova Y, et al
    Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer.
    Am J Clin Oncol. 2025 Apr 3. doi: 10.1097/COC.0000000000001195.
    PubMed     Abstract available
    
    
    March 2025
15. ADUWO JY, Burnette UJ, Onyewadume L, Stephens MJ, et al
    Early Cancer Screening Impressions of African-American Breast Cancer Patients Enrolled on the Navigator-Assisted Hypofractionation (NAVAH) Trial.
    Am J Clin Oncol. 2025 Mar 26. doi: 10.1097/COC.0000000000001189.
    PubMed     Abstract available
    
    
    
16. KASLIWAL N, Stephens MJ, Burnette UJ, Onyewadume L, et al
    Navigator-Assisted Hypofractionation (NAVAH) Phase I Clinical Trial of Breast Cancer Patients: Implications for Assessing Personal Versus Familial Financial Toxicity via the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic I
    Am J Clin Oncol. 2025 Mar 26. doi: 10.1097/COC.0000000000001190.
    PubMed     Abstract available
    
    
    
17. DAVIS KJ, Burnette UJ, Sun Y, Stephens MJ, et al
    Medical Racism and Physician Trust Impressions of African-American Breast Cancer Patients Enrolled on the Navigator-Assisted Hypofractionation (NAVAH) Phase I Clinical Trial.
    Am J Clin Oncol. 2025 Mar 3. doi: 10.1097/COC.0000000000001183.
    PubMed     Abstract available
    
    
    
18. QURESHI Z, Altaf F, Jamil A, Siddique R, et al
    Unlocking the Mysteries of Breast Cancer: The Role of Epigenetics in Diagnosis, Treatment, and Beyond.
    Am J Clin Oncol. 2025 Mar 3. doi: 10.1097/COC.0000000000001177.
    PubMed     Abstract available
    
    
    February 2025
19. CRUTTENDEN J, Grant J, Evans J, Cannon G, et al
    Impact of Consensus Guidelines, Clinical Trials, and COVID-19 on Fractionation Practices for Node-negative Intact Breast Cancer.
    Am J Clin Oncol. 2025 Feb 4. doi: 10.1097/COC.0000000000001167.
    PubMed     Abstract available
    
    
    December 2024
20. SANCHEZ JI, Doose M, Zeruto C, Chollette V, et al
    Assessing the Impact of Multidisciplinary Cancer Consultations on Cancer Quality Metrics.
    Am J Clin Oncol. 2024;47:595-606.
    PubMed     Abstract available
    
    
    
21. BOUZIANE J, Loap P, Cottu P, Escalup L, et al
    Concurrent Use of Radiotherapy and Ribociclib: Preliminary Results and Review of the Literature.
    Am J Clin Oncol. 2024;47:574-579.
    PubMed     Abstract available
    
    
    November 2024
22. CHOI JI, Freedman GM, Guttmann DM, Ahmed K, et al
    Executive Summary of the American Radium Society Appropriate Use Criteria: Regional Nodal Irradiation for Breast Cancer.
    Am J Clin Oncol. 2024 Nov 14. doi: 10.1097/COC.0000000000001154.
    PubMed     Abstract available
    
    
    
23. HASSANZADEH E, Sedighi Pashaki A, Akbari Hamed E, Mehrpooya M, et al
    Evaluating N-acetylcysteine as a Protective Agent Against Chemotherapy-induced Neuropathy in Breast Cancer: A Triple-blind, Randomized Clinical Trial.
    Am J Clin Oncol. 2024 Nov 4. doi: 10.1097/COC.0000000000001153.
    PubMed     Abstract available
    
    
    October 2024
24. LOAP P, Kirova Y
    Assessment of Radiotherapy as a Standalone Treatment Following Neoadjuvant Chemotherapy in Nonmetastatic Breast Cancer: A SEER Database Analysis.
    Am J Clin Oncol. 2024 Oct 4. doi: 10.1097/COC.0000000000001146.
    PubMed     Abstract available
    
    
    September 2024
25. QURESHI Z, Jamil A, Fatima E, Altaf F, et al
    Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Am J Clin Oncol. 2024 Sep 9. doi: 10.1097/COC.0000000000001143.
    PubMed     Abstract available
    
    
    
26. RITTER AR, Prasad RN, Jhawar SR, Bazan JG, et al
    Hypofractionated Radiation Therapy: A Cross-sectional Survey Study of US Radiation Oncologists.
    Am J Clin Oncol. 2024;47:434-438.
    PubMed     Abstract available
    
    
    
27. NAGAI M, Ewbank H, Po SS, Dasari TW, et al
    Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First-in-Human Randomized Pilot Study. Neuromodulation in Cancer Study (NCAN).
    Am J Clin Oncol. 2024;47:425-430.
    PubMed     Abstract available
    
    
    
28. KIM KW, Lopresti M, Graff SL, Witherby S, et al
    Fulfilling the Role of a Parent While Undergoing Treatment for Cancer: A Review of the Literature and the Potential Impact of Childcare Support on Cancer Outcomes.
    Am J Clin Oncol. 2024;47:445-447.
    PubMed     Abstract available
    
    
    July 2024
29. SANCHEZ-FELICIANO A, Onyewadume L, Stephens MJ, Flores LE, et al
    Validation of Spanish-Language Surveys Utilized for the Navigator-Assisted Hypofractionation (NAVAH) Program to Aid Hispanic-American Breast Cancer Patients.
    Am J Clin Oncol. 2024 Jul 26. doi: 10.1097/COC.0000000000001137.
    PubMed     Abstract available
    
    
    
30. BOUZIANE J, Loap P, Cao K, Allali S, et al
    Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: A Single-center Experience and Review of the Literature.
    Am J Clin Oncol. 2024 Jul 16. doi: 10.1097/COC.0000000000001135.
    PubMed     Abstract available
    
    
    
31. PUJARI L, Suresh A, Chowdhury Z, Pradhan S, et al
    Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and Metastasis Directed Radiotherapy.
    Am J Clin Oncol. 2024 Jul 4. doi: 10.1097/COC.0000000000001129.
    PubMed     Abstract available
    
    
    
32. QURESHI Z, Altaf F, Jamil A, Siddique R, et al
    Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+ and HER2-low Breast Cancer: An Updated Systematic Review and Meta-Analysis of Clinical Trials.
    Am J Clin Oncol. 2024 Jul 2. doi: 10.1097/COC.0000000000001126.
    PubMed     Abstract available
    
    
    June 2024
33. QURESHI Z, Jamil A, Fatima E, Altaf F, et al
    Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Comprehensive Systematic Review and Meta-analysis.
    Am J Clin Oncol. 2024 Jun 21. doi: 10.1097/COC.0000000000001121.
    PubMed     Abstract available
    
    
    
34. QURESHI Z, Jamil A, Altaf F, Siddique R, et al
    Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in Treatment of BRCA-mutated Breast Cancer: A Systematic Review and Meta-analysis.
    Am J Clin Oncol. 2024 Jun 20. doi: 10.1097/COC.0000000000001120.
    PubMed     Abstract available
    
    
    April 2024
35. NICHOLSON G, Carlson KB, Hernandez RK, Schenfeld J, et al
    Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
    Am J Clin Oncol. 2024;47:177-184.
    PubMed     Abstract available
    
    
    March 2024
36. MISTRY T, Nath A, Pal R, Ghosh S, et al
    Emerging Futuristic Targeted Therapeutics: A Comprising Study Towards a New Era for the Management of TNBC.
    Am J Clin Oncol. 2024;47:132-148.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.